View in EDS HTML Full Text PDF Full Text

Taletrectinib in ROS1+ non-small cell lung cancer: a cost-effectiveness analysis in the United States.

Saved in:
Bibliographic Details
Title: Taletrectinib in ROS1+ non-small cell lung cancer: a cost-effectiveness analysis in the United States.
Authors: Huo G; Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, China., Wang X; Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, China., Song Y; Department of Pharmacy, Jining NO.1 People's Hospital, Jining, Shandong, China., Tian Y; Medical Insurance Office, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China., Chen P; Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Source: Frontiers in pharmacology [Front Pharmacol] 2026 Apr 13; Vol. 17, pp. 1684603. Date of Electronic Publication: 2026 Apr 13 (Print Publication: 2026).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42051253
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Taletrectinib in ROS1+ non-small cell lung cancer: a cost-effectiveness analysis in the United States.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Huo+G%22">Huo G</searchLink>; Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, China.<br /><searchLink fieldCode="AU" term="%22Wang+X%22">Wang X</searchLink>; Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, China.<br /><searchLink fieldCode="AU" term="%22Song+Y%22">Song Y</searchLink>; Department of Pharmacy, Jining NO.1 People's Hospital, Jining, Shandong, China.<br /><searchLink fieldCode="AU" term="%22Tian+Y%22">Tian Y</searchLink>; Medical Insurance Office, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China.<br /><searchLink fieldCode="AU" term="%22Chen+P%22">Chen P</searchLink>; Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101548923%22">Frontiers in pharmacology</searchLink> [Front Pharmacol] 2026 Apr 13; Vol. 17, pp. 1684603. <i>Date of Electronic Publication: </i>2026 Apr 13 (<i>Print Publication: </i>2026).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Media]%22">Frontiers Media] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101548923 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>1663-9812 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2216639812%22">16639812 </searchLink><i>NLM ISO Abbreviation: </i>Front Pharmacol <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42051253
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fphar.2026.1684603
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1684603
    Titles:
      – TitleFull: Taletrectinib in ROS1+ non-small cell lung cancer: a cost-effectiveness analysis in the United States.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Huo G
      – PersonEntity:
          Name:
            NameFull: Wang X
      – PersonEntity:
          Name:
            NameFull: Song Y
      – PersonEntity:
          Name:
            NameFull: Tian Y
      – PersonEntity:
          Name:
            NameFull: Chen P
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 13
              M: 04
              Text: 2026 Apr 13
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-print
              Value: 1663-9812
          Numbering:
            – Type: volume
              Value: 17
          Titles:
            – TitleFull: Frontiers in pharmacology
              Type: main
ResultId 1